Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;9(2):331-8.
doi: 10.1177/1932296814557860. Epub 2014 Nov 10.

Are you ready for more insulin concentrations?

Alissa R Segal  1 , Nuha El Sayed  2
Affiliations
Review

Are you ready for more insulin concentrations?

Alissa R Segal et al. J Diabetes Sci Technol. 2015 Mar.

Abstract

Practitioners need to prepare for a rapid expansion of new concentrated insulins. For many years, the treatment regimens for patients have been limited to 2 concentrations (100 units/mL and 500 units/mL), which pose challenges to both patients and providers. As the new concentrated insulins are at various stages of development, this manuscript reviews the available information on the new concentrated products. This information was obtained from publications, poster presentations, abstracts, and the manufacturers for the products in earlier stages of development. To have a basis for comparison, it is important to understand the activity profile and the challenges with use of the currently available concentrated insulin, regular insulin 500 units/mL (U500R). We also examine how the newer products may assist clinicians and patients with the difficulties faced with the use of U500R.

Keywords: U-200 degludec insulin; U-300 glargine insulin; U-500 regular insulin; concentrated insulin therapy; subcutaneous injection.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3-19. - PubMed
    1. Rodbard H, Handelsman Y, Gough S, Dykiel P, Lassota N, Lane W. Reduced risk of hypoglycemia with insulin degludec vs insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: meta-analysis of five randomized trials [abstract] Endocr Pract. 2012:A45 Available at: https://www.aace.com/files/abstracts-2012.pdf. - PubMed
    1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613-1624. - PubMed
    1. De La Pena A, Ma X, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014;8(4):821-829. - PMC - PubMed
    1. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67:1526-1535. - PubMed

MeSH terms